07/15/2014 - 12:40pm

The National Association of Chain Drug Stores on Tuesday put forward pharmacy-specific solutions as the Senate Finance Committee conducted a hearing on “Chronic Illness: Addressing Patients’ Unmet Needs.”


07/15/2014 - 9:56am

Former Republican Speaker of the House J. Dennis Hastert last week wrote an editorial for the Washington Times supporting the use of such tamper-resistant pseudoephedrine products as Acura Pharmaceuticals' Nexafed and Westport Pharmaceuticals' Zephrex-D.

07/14/2014 - 11:51am

Teva Pharmaceuticals on Monday announced that the Food and Drug Administration has accepted the company's new drug application for albuterol multi-dose dry-powder inhaler, a breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease.

07/11/2014 - 11:38am

Anacor Pharmaceuticals announced that the Food and Drug Administration has approved the company's new drug application for Kerydin (tavaborole) topical solution, 5% — an antifungal approved for the topical treatment of onychomycosis of the toenails.

07/10/2014 - 7:39pm

A survey co-released by the Generic Pharmaceutical Association and the National Coalition on Healthcare reveals that 8-in-10 healthcare providers have serious concerns about a proposed Food and Drug Administration rule on generic drug labeling.

07/10/2014 - 7:38pm

A wave of new drug introductions and healthcare policy changes has had a significant impact on women’s health care over the past year.

07/10/2014 - 11:34am

The Food and Drug Administration on Wednesday shut down a company for noncompliance of the dietary supplement current good manufacturing practice requirements. 

07/10/2014 - 10:36am

The Food and Drug Administration in late June issued a warning letter to Zarbee's for making therapeutic claims regarding a dietary supplement product.

07/10/2014 - 10:04am

The Office of National Drug Control Policy released the 2014 National Drug Control Strategy, the Obama Administration’s primary blueprint for drug policy in the United States.